Page last updated: 2024-08-16

resveratrol and Hypertriglyceridemia

resveratrol has been researched along with Hypertriglyceridemia in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aragonès, G; Ardid-Ruiz, A; Arola, L; Bladé, C; Del Rio, D; Ibars, M; Mena, P; Muguerza, B; Suárez, M	1
Dash, S; Lewis, GF; Morgantini, C; Szeto, L; Xiao, C	1
Cogger, VC; Desbiens, M; Garand, C; Labbé, A; Le Couteur, DG; Lebel, M; Paquet, ER	1

Trials

1 trial(s) available for resveratrol and Hypertriglyceridemia

Article	Year
High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men. Arteriosclerosis, thrombosis, and vascular biology, 2013, Volume: 33, Issue:12 Topics: Adult; Analysis of Variance; Apolipoprotein B-100; Apolipoprotein B-48; Biomarkers; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Insulin Resistance; Intestinal Mucosa; Intestines; Lipoproteins; Liver; Male; Middle Aged; Obesity; Ontario; Overweight; Resveratrol; Stilbenes; Time Factors; Treatment Outcome; Triglycerides	2013

Article

Year

High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men.

Arteriosclerosis, thrombosis, and vascular biology, 2013, Volume: 33, Issue:12

Topics: Adult; Analysis of Variance; Apolipoprotein B-100; Apolipoprotein B-48; Biomarkers; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Insulin Resistance; Intestinal Mucosa; Intestines; Lipoproteins; Liver; Male; Middle Aged; Obesity; Ontario; Overweight; Resveratrol; Stilbenes; Time Factors; Treatment Outcome; Triglycerides

2013

Other Studies

2 other study(ies) available for resveratrol and Hypertriglyceridemia

Article	Year
Potential Involvement of Peripheral Leptin/STAT3 Signaling in the Effects of Resveratrol and Its Metabolites on Reducing Body Fat Accumulation. Nutrients, 2018, Nov-14, Volume: 10, Issue:11 Topics: Adipose Tissue; Animals; Antioxidants; Diet; Dose-Response Relationship, Drug; Gene Expression Regulation; Hypertriglyceridemia; Leptin; Male; Rats; Rats, Wistar; Resveratrol; Signal Transduction; STAT3 Transcription Factor; Weight Gain	2018
Resveratrol improves insulin resistance hyperglycemia and hepatosteatosis but not hypertriglyceridemia, inflammation, and life span in a mouse model for Werner syndrome. The journals of gerontology. Series A, Biological sciences and medical sciences, 2011, Volume: 66, Issue:3 Topics: Animals; Anticarcinogenic Agents; Disease Models, Animal; Fatty Liver; Hyperglycemia; Hypertriglyceridemia; Inflammation; Insulin Resistance; Mice; Mice, Inbred C57BL; Resveratrol; Stilbenes; Werner Syndrome	2011

Article

Year

Potential Involvement of Peripheral Leptin/STAT3 Signaling in the Effects of Resveratrol and Its Metabolites on Reducing Body Fat Accumulation.

Nutrients, 2018, Nov-14, Volume: 10, Issue:11

Topics: Adipose Tissue; Animals; Antioxidants; Diet; Dose-Response Relationship, Drug; Gene Expression Regulation; Hypertriglyceridemia; Leptin; Male; Rats; Rats, Wistar; Resveratrol; Signal Transduction; STAT3 Transcription Factor; Weight Gain

2018

Resveratrol improves insulin resistance hyperglycemia and hepatosteatosis but not hypertriglyceridemia, inflammation, and life span in a mouse model for Werner syndrome.

The journals of gerontology. Series A, Biological sciences and medical sciences, 2011, Volume: 66, Issue:3

Topics: Animals; Anticarcinogenic Agents; Disease Models, Animal; Fatty Liver; Hyperglycemia; Hypertriglyceridemia; Inflammation; Insulin Resistance; Mice; Mice, Inbred C57BL; Resveratrol; Stilbenes; Werner Syndrome

2011